MaxCyte to Participate in Three Upcoming Investor Conferences
MaxCyte (MXCT) management will participate in three investor conferences in November, including fireside chats at the Stifel and Stephens conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MaxCyte (MXCT) management will participate in three investor conferences in November, including fireside chats at the Stifel and Stephens conferences.
The Stifel chat is November 11 at 4:40 PM ET; the Craig-Hallum Alpha Select conference is November 17; and the Stephens chat is November 18 at 9:30 AM CT. Live and archived webcasts will be available in the Events section of MaxCyte’s investor relations website.
Details
Market Reaction – MXCT
On Oct 28, the day this news came out, the latest delayed price for MXCT is 5.99% above the previous close. Our momentum scanner has recorded 11 alerts for this stock so far that day. The latest delayed price is $1.63. Relative volume is very high at 3.5x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKVILLE, Md., Oct. 28, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics, today announced Company management will participate in three upcoming investor conferences.
- Stifel 2026 Healthcare Conference
Fireside Chat on Wednesday, November 11th at 4:40 PM ET - 17th Annual Craig-Hallum Alpha Select Conference
Tuesday, November 17th - Stephens Annual Investment Conference
Fireside Chat on Wednesday, November 18th at 9:30 AM CT
A live and archived webcast of the events will be available on the “Events” section of the MaxCyte investor relations website at https://investors.maxcyte.com/.
About MaxCyte
At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure™ gene editing risk assessment services enable high-performance cell engineering and rigorous evaluation of editing outcomes, supporting confidence in therapeutic development. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine.
Learn more at maxcyte.com and follow us on LinkedIn and Bluesky.
MaxCyte Contacts:
Investor Relations
Gilmartin Group
Erik Abdow
ir@maxcyte.com
Media Contact
Oak Street Communications
Kristen White
kristen@oakstreetcommunications.com
415.608.6060
